Tune in to the <https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.facebook.com%2FDENStudentPrograms%2F&data=02%7C01%7CMichael.Zhang.21%40dartmouth.edu%7C44366588cc534fd4c12308d5a611bb7f%7C995b093648d640e5a31ebf689ec9446f%7C0%7C0%7C636597517483162828&sdata=rNGthRW0zd2bhNESUMznPrlp7W%2Brvj7zu%2FXbSAzKJSo%3D&reserved=0> DEN Student Programs Facebook page<https://www.facebook.com/DENStudentPrograms/> at 9:00 pm Thursday, May 17, to hear a DEN 1-1 live-streamed interview with Sourav Sinha<https://www.forbes.com/forbes/welcome/?toURL=https://www.forbes.com/profile/sourav-sinha/&refURL=https://www.google.com/&referrer=https://www.google.com/> '12, CEO and Co-Founder of a bio-tech company, Oncolinx<https://www.oncolinx.com/>.


Oncolinx<https://www.oncolinx.com/> is a biotechnology company developing targeted therapies that enhance the immune system's ability to target tumors while killing cancer cells. Additionally, he is a co-founding executive at Celularity, which just received around 300 million dollars in Series A funding to develop life-changing placental cell therapies and regenerative medicines.


About Sourav: Sourav received an AB in Molecular Biochemistry from Dartmouth in 2012 and graduated from Singularity University's Global Solutions Program in 2016. During his time at Dartmouth, he published as a co-author in Nature: Methods and Cell, two of the world's most prestigious scientific journals. He was also a member of the Dartmouth Men’s Rugbyteam, which won the 2011 and 2012 Collegiate Division I National Championships.


[cid:a6e3d6c3-f3df-40b3-a69b-283e9f726b54]